The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: De Stefano, Valerio, Rocca, Bianca, Tosetto, Alberto, Soldati, Denise, Petrucci, Giovanna, Beggiato, Eloise, Bertozzi, Irene, Betti, Silvia, Carli, Giuseppe, Carpenedo, Monica, Cattaneo, Daniele, Cavalca, Viviana, Dragani, Alfredo, Elli, Elena, Finazzi, Guido, Iurlo, Alessandra, Lanzarone, Giuseppe, Lissandrini, Laura, Palandri, Francesca, Paoli, Chiara, Rambaldi, Alessandro, Ranalli, Paola, Randi, Maria Luigia, Ricco, Alessandra, Rossi, Elena, Ruggeri, Marco, Specchia, Giorgina, Timillero, Andrea, Turnu, Linda, Vianelli, Nicola, Vannucchi, Alessandro M., Rodeghiero, Francesco, Patrono, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992153/
https://www.ncbi.nlm.nih.gov/pubmed/29880847
http://dx.doi.org/10.1038/s41408-018-0078-3

Ejemplares similares

Ejemplares similares